2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 837

Rheumatoid Arthritis and Risk for Chronic Obstructive Pulmonary Disease or Asthma Among Women during 38 Years of Prospective Follow-up
Abstract Number: 137

Rheumatoid Arthritis and the Risk for Interstitial Lung Disease: A Comparison of Risk Associated with Biologic and Conventional Dmards
Abstract Number: 2399

Rheumatoid Arthritis Have Lower Glomerular Filtration Rate Compared to Healthy Population: Role of Inflammation
Abstract Number: 244

Rheumatoid Arthritis Imaging on PET-CT Using a Novel Folate Receptor Ligand for Macrophage Targeting
Abstract Number: 475

Rheumatoid Arthritis Patient Characteristics Also Predict Response to Therapy with Biologic Agents: Results from the Corrona Certain Study
Abstract Number: 440

Rheumatoid Arthritis Patient´s Journey: Delay in Diagnosis and Treatment
Abstract Number: 1083

Rheumatoid Arthritis Patients Achieved Better Quality of Life Than Systemic Lupus Erythematosus Patients at Sustained Remission: The Impact of Disease Diagnosis on Health-Related Quality of Life Outcomes
Abstract Number: 471

Rheumatoid Arthritis Patients Resistant to Biologic Therapy, Are They Different?
Abstract Number: 165

Rheumatoid Arthritis Risk Polymorphisms in CCR6, SNP and Estrogen-Dependent Response to Immune Mediator Gene Expression, and NF-κb Transcriptional Activity: Crosstalk between the Immune and Endocrine Systems
Abstract Number: 2401

Rheumatoid Arthritis with Kidney Dysfunction Contributes to Higher Risk of Cardiovascular Disease Development
Abstract Number: 2741

Rheumatoid Factor (RF) Levels Remain Persistently Elevated 24 Weeks after Interferon (INF) Free Direct Antiviral Agents (DAA) Therapy in the Majority of RF+ HCV Infected Persons
Abstract Number: 2119

Rheumatological Immune Related Adverse Events in Malignancy Patients Treated with Anti-Programmed Cell Death (PD) 1 Antibodies
Abstract Number: 2498

Rheumatologists Use Different Cut-Offs for Disease Activity in Real Life – the Experience with Golimumab in Ankylosing Spondylitis- Subanalysis from a Non-Interventional German Study
Abstract Number: 2036

Rheumatologists’ Compliance with Screening for Viral Hepatitis B and C Prior to Initiation of Methotrexate Treatment Needs Quality Improvement
Abstract Number: 1087

Rheumatology Clinic Smoking Cessation Protocol Markedly Increases Quit Line Referrals

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].